The study conducted by Dr. Erminia Massarelli focused on evaluating the combination of osimertinib and consolidative stereotactic ablative radiation (SABR) for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC). This study was carried out in collaboration with UT Southwestern and included 43 untreated patients with metastatic and incurable disease. The results of the